Prognosis of BRCA-associated breast cancer: a summary of evidence

Bordeleau, L.; Panchal, S.; Goodwin, P.

doi:10.1007/s10549-009-0566-z

Cited by 135BRCA gene mutations in cancerMultiple and Secondary Primary CancersBreast Cancer Treatment Studies

Prognosis of BRCA-associated breast cancer: a summary of evidence

Bordeleau, L., Panchal, S., Goodwin, P.·2010·Breast Cancer Research and Treatment

DOI 10.1007/s10549-009-0566-z

Open this paper in CoChat — free account

Abstract

The purpose of the study is to review the clinical studies relevant to the prognosis and prognostic associations of BRCA1- and BRCA2-associated breast cancers. Reports of relevant studies obtained from a MEDLINE search and references from these articles were critically reviewed. A number of methodologic limitations have been identified in the early studies. More recent studies have failed to demonstrate, for the most part, a significant overall survival difference between BRCA-associated breast cancers and sporadic breast cancers. The risk of in-breast tumor recurrence also appears to be similar in the first 5 years following a breast cancer diagnosis with apparent increase in the risk after 5 years in one study. Many in-breast tumor recurrences are now considered to be second primary breast cancers. There is a significant increase in the risk of contralateral breast cancers in BRCA mutation carriers with an estimated 10-year risk ranging from 20-40%. The prognosis of BRCA-associated breast cancers appears to be similar to that of sporadic breast cancers based on the current literature. Future data from large prospective cohort studies will be of interest.

Integrity signals

Registry

Crossref · 10.1007/s10549-009-0566-z

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The risk of contralateral cancer was significantly higher 5 to 10 years after first diagnosis in BRCA1/2 mutation carriers, ranging from 20 to 42%, compared with 5% and 6% in non-carriers.
“Bordeleau et al. [14] found that the risk of contralateral cancer was significantly higher 5 to 10 years after first diagnosis in carriers, ranging from 20 to 42%, compared with 5% and 6% in non-carriers.”
From Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study (2024) · cites this paper as [14]
Women with a BRCA1/2 genetic mutation who have been treated for breast cancer are at increased risk of having a local recurrence or a second primary cancer.
“In addition to having an increased risk of developing a first breast cancer, women with a BRCA1/2 genetic mutation and who have been treated for breast cancer are also at an increased risk of having a local recurrence or a second primary cancer.”
From Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study (2024) · cites this paper as [14]

Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · see citing works
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544 · see citing works
Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K. N., Seal, S., Tran, T. D., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,918 · see citing works
Gene-expression profiles in hereditary breast cancer.
Hedenfalk, I., Duggan, D., Chen, Y.-D., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 978 · see citing works
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967 · see citing works
Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707 · see citing works
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Warner, E., Olopade, O. I., Eisen, A. F., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 620 · see citing works
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod, S., Brunet, J., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., Ríos, P. D. L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 557 · see citing works
Familial breast-ovarian cancer locus on chromosome 17q12-q23
Lenoir, G. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)90076-2 · Cited by 519 · see citing works
An overview of prognostic factors for long-term survivors of breast cancer
Soerjomataram, I., Louwman, M. W. J., Ribot, J. G., Roukema, J. A., & Coebergh, J. W. W. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9556-1 · Cited by 513 · see citing works
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452 · see citing works
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Atchley, D. P. D., Albarracin, C., López, A., Valero, V., Amos, C., González-Angulo, A., Hortobagyi, G., & Arun, B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6231 · Cited by 411 · see citing works
Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in <i>BRCA1/2</i>-Associated Stage I/II Breast Cancer
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340 · see citing works
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307 · see citing works
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307 · see citing works
BRCA-associated breast cancer in young women.
Robson, M. E., Gilewski, T., Haas, B. R., Levin, D. R., Borgen, P. I., Rajan, P., Hirschaut, Y., Pressman, P., Rosen, P. P., LESSER, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1642 · Cited by 303 · see citing works
Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations
Rennert, G., Bisland-Naggan, S., Barnett‐Griness, O., Bar-Joseph, N., Zhang, S., Rennert, H. S., & Narod, S. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070608 · Cited by 300 · see citing works
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
van Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R. M., van Asperen, C. J., Rutgers, E. J. T., Veer, L. J. V., & Tollenaar, R. A. �. �. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602703 · Cited by 291 · see citing works
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
Pierce, L., Strawderman, M., Narod, S., Oliviotto, I., Eisen, A., Dawson, L., Gaffney, D., Solin, L., Nixon, A., Garber, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3360 · Cited by 270 · see citing works
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254 · see citing works
Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode, E. L., Dunning, A. M., Kuschel, B., Healey, C. S., Day, N., Ponder, B. A. J., Easton, D. F., & Pharoah, P. D. P. (2002) · PubMed · Cited by 239 · see citing works
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
Brekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233 · see citing works
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Stoppa-Lyonnet, D., Ansquer, Y., Dreyfus, H., Gautier, C., Gauthier-Villars, M., Bourstyn, E., Clough, K., Magdelénat, H., Pouillart, P., Vincent-Salomon, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4053 · Cited by 224 · see citing works
Closing in on a breast cancer gene on chromosome 17q.
Hall, J., Friedman, L. S., Guenther, C. A., et al. (1992) · PubMed · Cited by 215 · see citing works
Survival in hereditary breast cancer associated with germline mutations of BRCA2.
Verhoog, L., Brekelmans, C., Seynaeve, C., Dahmen, G., van Geel, A. V., Bartels, C., Tilanus-Linthorst, M., Wagner, A., Devilee, P., Halley, D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3396 · Cited by 197 · see citing works
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Robson, M., Levin, D., Federici, M. G., Satagopan, J. M., Bogolminy, F., Heerdt, A., Borgen, P., Mccormick, B., Hudis, C., Norton, L., et al. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2112 · Cited by 181 · see citing works
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios, J., Honrado, E., Osório, A., Cazorla, A., Sarrió, D., Barroso, A., Rodríguez, S., Cigudosa, J. C., Dı́ez, O., Alonso, C., et al. (2003) · PubMed · Cited by 175 · see citing works
The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis
Lucas, K. G., Brown, A. E., Armstrong, D., Chapman, D. S., & Heller, G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4 · Cited by 174 · see citing works
Survival and prognostic factors in BRCA1-associated breast cancer.
Brekelmans, C., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H., Tilanus-Linthorst, M., Bartels, C., Kriege, M., van Geel, A. V., Crepin, C., Blom, J., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj095 · Cited by 147 · see citing works
Natural history of hereditary cancer of the breast and colon
Albano, W. A., Recabaren, J. A., Lynch, H. T., et al. (1982) · Cancer · doi:10.1002/1097-0142(19820715)50:2 · Cited by 143 · see citing works
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129 · see citing works
Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12–21
Porter, D., Cohen, B. B., Wallace, M. R., Smyth, E., Chetty, U., Dixon, J. M., Steel, C. M., & Carter, D. C. (1994) · British journal of surgery · doi:10.1002/bjs.1800811038 · Cited by 122 · see citing works
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
Foulkes, W. D., Wong, N., Brunet, J., Bégin, L. R., Zhang, J. C., Martinez, J. J., Rozen, F., Tonin, P. N., Narod, S. A., Karp, S. E., et al. (1997) · PubMed · Cited by 122 · see citing works
Germline BRCA1/2 Mutations and p27Kip1 Protein Levels Independently Predict Outcome After Breast Cancer
Chappuis, P. O., Kapusta, L. R., Bégin, L. R., Wong, N., Brunet, J., Narod, S. A., Slingerland, J. M., & Foulkes, W. D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4045 · Cited by 119 · see citing works
Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy
Møller, P., Borg, Å., Evans, D. G., Kingsbury, N., Reis, M. M., Vasen, H. F. A., Anderson, E. D. C., Steel, C. M., Apold, J., Goudie, D. R., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10641 · Cited by 113 · see citing works
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Lee, J. S., Wacholder, S., Struewing, J., McAdams, M., Pee, D., Brody, L., Tucker, M. A., & Hartge, P. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.259 · Cited by 113 · see citing works
Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations
Gaffney, D. K., Brohet, R. M., Lewis, C. M., et al. (1998) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(98)00023-1 · Cited by 110 · see citing works
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status
Møller, P., Evans, D. G., Reis, M. M., Gregory, H., Anderson, E. D. C., Mæhle, L., Lalloo, F. I., Howell, A., Apold, J., Clark, N., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22789 · Cited by 95 · see citing works
Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases
Veronesi, A., de Giacomi, C., Magri, M. D., Lombardi, D., Zanetti, M., Scuderi, C., Dolcetti, R., Viel, A., Crivellari, D., Bidoli, E., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-70 · Cited by 94 · see citing works
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
Foulkes, W. D., Chappuis, P. O., Wong, N., Brunet, J.-S., Vesprini, D., Rozen, F., Yuan, Z. Q., Pollak, M. N., Kuperstein, G., Narod, S. A., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008340723974 · Cited by 86 · see citing works
Prognosis of Breast Cancer in Carriers ofBRCA1andBRCA2Mutations
Goodwin, P. J., Phillips, K.-A., & West, D. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmc072301 · Cited by 82 · see citing works
Self-citation
Survival in early-onset BRCA1 breast-cancer patients
Ansquer, Y., Gautier, C., Fourquet, A., Asselain, B. J. R., & Stoppa‐Lyonnet, D. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79248-5 · Cited by 80 · see citing works
Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma
Mai, P. L., Chatterjee, N., Hartge, P. A., Tucker, M. A., Brody, L. C., Struewing, J. P., & Wacholder, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004812 · Cited by 71 · see citing works
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland
Eerola, H., Vahteristo, P., Sarantaus, L., nen, P. K., Pyrh�nen, S., BLOMQVIST, C. P., Pukkala, ., Nevanlinna, H. A., & Sankila, R. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1341 · Cited by 65 · see citing works
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review
Bonadona, V., Dussart, S., Voirin, N., Sinilnikova, O. M., Mignotte, H., Mathevet, P., Bremond, A. G., Treilleux, I., Martin, A., Romestaing, P., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9288-7 · Cited by 51 · see citing works
Survival and tumor characteristics of German hereditary breast cancer patients
Hamann, U., & Sinn, H.-P. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006350518190 · Cited by 48 · see citing works
Prognosis and clinical presentation of BRCA2-associated breast cancer
Loman, N., Johannsson, O., Bendahl, P.-O., Dahl, N., Einbeigi, Z., Gerdes, A.-M., Borg, Å., & Olsson, H. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00098-8 · Cited by 46 · see citing works
Breast cancer survival in BRCA1 carriers
Porter, D., Dixon, M., Smyth, E., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)90052-i · Cited by 42 · see citing works
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients
Kriege, M., Seynaeve, C., Meijers-Heijboer, H. E. J., Collee, M. J., Menke‐Pluymers, M. B. E., Bartels, C. C. M., Tilanus‐Linthorst, M. M. A., van den Ouweland, A., van Geel, B., Brekelmans, C. T. M., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9781-7 · Cited by 36 · see citing works
Low frequency of lymph-node metastasis in BRCA1-associated breast cancer
Eisinger, F., Noguès, C., Birnbaum, D., Jacquemier, J. D., & Sobol, H. (1998) · The Lancet · doi:10.1016/s0140-6736(05)77689-3 · Cited by 26 · see citing works
Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India.
Vinodkumar, B., Syamala, V. S., Abraham, E. K., et al. (2007) · PubMed · Cited by 10 · see citing works
BRCA1, pathology, and survival.
Lynch, H. T., & Watson, P. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.395 · Cited by 6 · see citing works

Flagged first, then by citations

Sorted by citations

High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer
Nilsson, M. P., Hartman, L., Kristoffersson, U., Johannsson, O. T., Borg, Å., Henriksson, K., Lanke, E., Olsson, H., & Loman, N. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3115-3 · Cited by 56 · see citing works
Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study
Michel, A., Dorval, M., Chiquette, J., & Savard, J. (2024) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-024-00285-5 · Cited by 3 · see citing works
“Bordeleau et al. [14] found that the risk of contralateral cancer was significantly higher 5 to 10 years after first diagnosis in carriers, ranging from 20 to 42%, compared with 5% and 6% in non-carriers.”
Result

High peroxidasin-like expression is a potential and independent prognostic biomarker in breast cancer
Li, Y., Jiao, Y., Luo, Z., Li, Y., & Liu, Y. (2019) · Medicine · doi:10.1097/md.0000000000017703 · Cited by 25 · see citing works
Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer
Fu, F., Guo, W., Lin, Y., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1634-0 · Cited by 4 · see citing works
Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy
Matsen, C. B. (2016) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2016.10.004
The American Cancer Society guidelines for breast screening with magnetic resonance imaging
Murphy, C., Lee, J. M., Drohan, B., et al. (2008) · Cancer · doi:10.1002/cncr.23913 · Cited by 28 · see citing works
Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers
Lubiński, J., Huzarski, T., Gronwald, J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05076-w · Cited by 10 · see citing works

Authors: Bordeleau, L., Panchal, S., & Goodwin, P.
Affiliations: Juravinski Cancer Centre (CA)
Mount Sinai Hospital (CA)
Corresponding author: Bordeleau, L.
ORCID: Bordeleau, L.
Goodwin, P.
Venue: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Published: 2009-09-30
Volume: 119
Issue: 1
Pages: 13-24
ISSN: 0167-6806 (ISSN-L)
1573-7217
DOI: 10.1007/s10549-009-0566-z
OpenAlex: W1990635160
Cited by: 135
References: 52
Citations by year: 2026: 1 · 2025: 3 · 2024: 9 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 7 · 2018: 8 · 2017: 8 · 2016: 9 · 2015: 7 · 2014: 14 · 2013: 12 · 2012: 9
FWCI: 0.98
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Breast Cancer Research and Treatment (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: BRCA1, BRCA2, hereditary breast cancer, prognosis, overall survival, tumor recurrence, second primary breast cancer, contralateral breast cancer, BRCA mutation carriers
MeSH terms: Adult, Breast Neoplasms, Female, Humans, Middle Aged, Prognosis, Recurrence, Risk, Time Factors, Case-Control Studies, Treatment Outcome, BRCA1 Protein, Genes, BRCA1, Genes, BRCA2, BRCA2 Protein, Apoptosis Regulatory Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prognosis of BRCA-associated breast cancer: a summary of evidence

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks